Welcoming Victor Bornsztejn as Senior Vice President of Commercial
January 21, 2025 09:00 ET
|
Culture Biosciences
SAN FRANCISCO, CALIFORNIA, UNITED STATES, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Culture Biosciences, a leader in cloud-connected bioprocessing technologies, is pleased to announce the appointment of...
Viral Vectors-Based Gene Therapy for Non-Human Primates to Account for a Market Share of Over US$ 92.76 Million by 2034, Growing at a 11.0% CAGR, Latest Report by TMR
January 16, 2025 11:00 ET
|
Transparency Market Research
Wilmington, Delaware, Transparency Market Research Inc. –, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Viral Vectors-Based Gene Therapy for Non-Human Primates Market Outlook – Accelerating Growth and Future...
Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Research 2024-2033: Robust Growth Fueled by Disease Prevalence and Therapy Approvals, AI and Real-time Testing Trends Set to Shape Future
January 16, 2025 07:41 ET
|
Research and Markets
Dublin, Jan. 16, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Cell and Gene Therapy Manufacturing QC Market: Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's...
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
January 16, 2025 07:30 ET
|
Ocugen
MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
CRISPR-based Gene Editing Market Report 2025, with Company Profiles of the Top 10+ Major Market Players
January 13, 2025 11:45 ET
|
Research and Markets
Dublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added to ...
Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa
January 13, 2025 06:30 ET
|
Ocugen
100% (9/9) of treated evaluable subjects demonstrated improvement or preservation in visual function compared to untreated eyes at both one and two years100% (9/9) of treated evaluable subjects...
Ori Biotech Expands Team to Advance IRO Commercialization and Industry Partnerships
January 09, 2025 08:30 ET
|
Oribiotech Ltd
Ori Biotech announces the appointment of two new members to its senior team and new members to its Strategic Advisory Board (SAB).
Coave Therapeutics lève €32 millions d'euros en série A pour accélérer le développement de ses médicaments génétiques de nouvelle génération
January 09, 2025 03:00 ET
|
Coave Therapeutics
Le tour de table a été mené par Novo Holdings A/S et Bpifrance (dans le cadre de la stratégie d'investissement InnoBio), avec la participation d'investisseurs américains et européens, Invus et UI...
Coave Therapeutics Secures €32 Million ($33 Million) in Series A Financing to Advance its Next-Generation Genetic Medicines
January 09, 2025 03:00 ET
|
Coave Therapeutics
Financing co-led by Novo Holdings A/S and Bpifrance (as part of the InnoBio investment strategy) and joined by leading US and EU investors Invus and UI Investissement alongside existing...
Breakthrough Gene Editing Technique Offers Hope for Stargardt Disease Patients
January 08, 2025 13:30 ET
|
Institute of Molecular and Clinical Ophthalmology Basel (IOB)
Researchers have developed a highly efficient gene editing therapy that could potentially treat Stargardt disease, the most common form of inherited macular degeneration. This groundbreaking study,...